Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is a biopharmaceutical company engaged in the development of its drug candidate SCENESSE® (afamelanotide 16mg) for the treatment of a range of severe skin disorders. SCENESSE®, a drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the U.S. and Europe and has been approved by the European Commission for treating adults with EPP. Co.'s products aims at preventing the symptoms of skin diseases related to the exposure to harmful Ultraviolet radiation and at repigmentation of the skin due to a number of depigmentation disorders. Co. has operations in Europe, the U.S. and Singapore.
  • TickerCUV
  • ISINAU000000CUV3
  • ExchangeAustralian Securities Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryAustralia

Analysts

Clinuvel Pharmaceuticals Limited: 1 director bought

A director at Clinuvel Pharmaceuticals Limited bought 1,093 shares at 27.437AUD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. ...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

Peter Thilo Hasler

FDA approval for Scenesse

The US Food and Drug Administration approved Clinuvel’s Scenesse treatment for EPP (erythropoietic protoporphyria) as a new molecular entity and medical innovation in the United States. EPP is a rare genetic disorder of the heme biosynthesis pathway which causes severe anaphylactoid reactions and burns (phototoxicity) following even brief exposure to visible light, both of artificial and natural light sources. With the approved new drug application (NDA), Scenesse becomes the first global systemic photoprotective drug for the treatment of patients with EPP, since the drug has been approved in ...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior